Identifying Adult Dengue Patients at Low Risk for Clinically Significant Bleeding

Joshua G. X. Wong¹²*, Tun Linn Thein¹, Yee-Sin Leo¹³⁴⁵, Junxiong Pang¹⁴, David C. Lye¹⁵

¹ Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore, ² Department of Clinical Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore, ³ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore, ⁴ Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁵ Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

* Joshua_Gx_Wong@ttsh.com.sg

Abstract

Background
Clinically significant bleeding is important for subsequent optimal case management in dengue patients, but most studies have focused on dengue severity as an outcome. Our study objective was to identify differences in admission parameters between patients who developed clinically significant bleeding and those that did not. We sought to develop a model for discriminating between these patients.

Methods
We conducted a retrospective study of 4,383 adults aged >18 years who were hospitalized with dengue infection at Tan Tock Seng Hospital, Singapore from 2005 to 2008. Patients were divided into those with clinically significant bleeding (n = 188), and those without (n = 4,195). Demographic, clinical, and laboratory variables on admission were compared between groups to determine factors associated with clinically significant bleeding during hospitalization.

Results
On admission, female gender (p<0.001); temperature >38°C (p<0.001); nausea/vomiting (p = 0.009) and abdominal pain/tenderness (p = 0.005); lower systolic blood pressure (p<0.001); higher pulse rate (p<0.001); increased absolute neutrophil count (ANC; p<0.001); reduced absolute lymphocyte count (ALC; p<0.001), haematocrit percentage (p<0.001) and platelet count (p = 0.04), and increased prothrombin time (p = 0.003) were significantly associated with clinically significant bleeding on univariate analysis. Multivariate analysis showed that independent variables in the final model were female gender (aOR 2.85; 95% CI: 1.9–4.33); temperature >38°C (aOR 1.81; 95% CI: 1.27–2.61), nausea/vomiting (aOR 1.39; 95% CI: 0.94–2.12), ANC (aOR 1.3; 95% CI: 1.15–1.46), ALC (aOR 0.4; 95% CI: 0.25–0.64), hematocrit percentage (aOR 0.96; 95% CI: 0.92–1.002) and
platelet count (aOR 0.993; 95% CI: 0.988–0.998). At the cutoff of -3.919, the model achieved an AUC of 0.758 (sensitivity: 0.87, specificity: 0.38, PPV: 0.06, NPV: 0.98).

Conclusion
Clinical risk factors associated with clinically significant bleeding were identified. This model may be useful to complement clinical judgement in triaging adult dengue patients given the dynamic nature of acute dengue, particularly in pre-identifying those less likely to develop clinically significant bleeding.

Introduction
Acute dengue infection is the most rapidly spreading mosquito-borne viral disease in the world.[1] Dengue is predominantly found in urban and semi-urban areas. The last 50 years has seen a 30-fold increase in its incidence worldwide. Once a disease that affected mainly Asia, Africa, Latin America and the Indian sub-continent, the virus has now spread to the Middle East, Europe, Australia and the USA.[1–7] The World Health Organization (WHO) has reported that over 40% of the global population is at risk of dengue.[8] A 2013 published burden estimate study indicated that there are 390 million infections per year, more than three times the WHO’s estimate.[9]

Over 70% of the worldwide population at risk for dengue lives in Southeast Asian and Western Pacific countries.[1] Previously, dengue in Southeast Asia affected predominantly children, but adults are increasingly being hospitalized with dengue.[10,11]

Dengue has a wide spectrum of clinical presentation. Patients may experience mild symptoms such as abdominal pain, fever or rash in a self-limiting, non-severe clinical course. A small proportion of patients progress to severe disease, which is defined as plasma leakage leading to shock (dengue shock syndrome; DSS) and/or fluid accumulation, with or without respiratory distress; severe bleeding; and/or severe organ impairment.[1] Adverse outcomes also include gastrointestinal bleeding, renal failure, hemoconcentration and abnormalities in hemostasis. Vascular leakage and shock tend to occur more frequently and be more severe in children, while bleeding manifestations and organ involvement are more common amongst adults.[10,12]

Regions of high dengue transmission frequently have seasonal epidemics, which can quickly overwhelm health services. Singapore has experienced several severe dengue outbreaks during the last decade. In 2004, there were 9,459 notified cases, with 83% of these patients being hospitalized.[13] In 2005, 14,209 cases were recorded, which resulted in 25 deaths. Despite continuing efforts to improve dengue surveillance and a world-class vector control program, Singapore experienced another dengue epidemic in 2013, involving 22,170 cases and seven deaths.[14]

The ability to identify patients at high risk of progression to severe bleeding who are likely to benefit from close observation and early intervention with supportive therapy is becoming increasingly important.[15] However, most studies were carried out to identify risk factors for progression focus on general dengue severity [10,12,16–21] or risk factors associated with death.[22–25] Fewer studies were carried out to determine risk factors for any bleeding [26–30]; these studies generally had relatively small patient populations, and the clinical and case definitions varied widely. Even fewer studies were conducted to determine risk factors for severe or clinically significant bleeding.[26,28]
In a study of the clinical characteristics of 6,989 adult patients who were treated for dengue between 2005 and 2008 at a Singapore tertiary hospital, 1,035 (14.8%) had severe dengue (SD) according to WHO 2009 criteria [1]; of these, 40% had severe bleeding [11]. A few cohort studies showed high prevalence of severe bleeding in dengue mortality. A local multi-center study showed elevated risk of death in severe dengue patients [24]. A Taiwanese study showed that massive gastrointestinal bleeding accounted for 40% of dengue hemorrhagic fatalities [25] while a Brazilian study showed 45% of those with gastrointestinal bleeding progressed to death [31]. The aim of this study was to identify simple clinical and laboratory variables that are associated with clinically significant bleeding (CSB) in adult patients who are admitted to hospital with dengue.

Methods

Ethics Statement

The study was approved by the National Healthcare Group Domain Specific Review Board (DSRB/E/2008/00567) with a waiver of informed consent for the collection of anonymized data.

Study Design and Population

This was a retrospective cohort study of all adult patients who were admitted to the Communicable Disease Center at Tan Tock Seng Hospital in Singapore between 1 January 2005 and 31 December 2008 with acute dengue infection. Patients were hospitalized if they were suspected of dengue hemorrhagic fever (DHF) or fulfilled the admission criteria as published in another study [32]. Patients were referred to intensive care unit if they had compensated shock (systolic blood pressure > 90 mmHg but narrow pulse pressure < 20 mmHg) and those with hypotension (systolic blood pressure < 90 mmHg). A standardized dengue care path was used to manage patients. On admission, we collected demographic data and information on patients’ past history of fever. Detailed data on clinical signs and/or symptoms, examination findings, microbiological and laboratory parameters were collected daily from hospital admission to discharge. The care path also provided clear criterion for intravenous fluids and blood products. Treatment decision on platelet transfusion was made by individual doctors. Patients without clinical bleeding were often given preventive platelet transfusion if their platelet count was below 20,000. If a patient had clinical bleeding, even though it may not be persistent or severe, often our doctors would administer platelet transfusion. Hospital electronic medical records were used to extract laboratory, microbiological, radiological, treatment and outcome data. Data extraction was performed by medically trained research assistants. More detailed description of the cohort has been described previously [11]. Each patient was assigned a Charlson co-morbidity score if they have any pre-existing illness [33].

Clinical fluid accumulation was defined as presence of lung dullness or shifting dullness or pleural effusion or ascites. DHF and DSS were classified as per WHO 1997 definitions [34].

Dengue patients who were eligible for this study were hospitalized adults aged 18 years or older who either met WHO 1997 or 2009 probable dengue criteria together with positive acute dengue serology (Dengue Duo IgM & IgG Rapid Strip, Panbio Diagnostic, Queensland, Australia), or had a positive RT-PCR result for dengue. Patients who had experienced any bleeding prior to or on the day of admission were excluded from the study.

Clinically significant bleeding (CSB) was defined as any of the following events as evaluated by the clinician: hematemesis, melena, fresh rectal bleeding, menorrhagia, hemoptysis, macroscopic hematuria, intracranial bleeding or a clinical drop in hemoglobin that required whole blood or packed red cell transfusion. These were chosen as they represent clinically significant events to a physician that require closer monitoring and/or further evaluation.
Statistical Analyses
All variables except the outcomes were evaluated on the day of admission. Variables with less than 10% missing data were imputed with their group medians, or otherwise excluded. Data were randomly split into training (80%) and validation sets (20%). Univariate analysis was performed using the Mann-Whitney test for continuous variables, and the Chi-squared and Fisher’s tests for categorical variables. Variables that had a p-value < 0.2 on univariate analysis, or which were considered to be clinically relevant (e.g., age) were subsequently analyzed with multivariate logistic regression to determine independently associated risk factors for CSB in adults. Stepwise regression using Akaike Information Criteria and manual backward elimination methods were carried out for model selection. Sensitivity was the primary measure of performance and was used to choose the final model. Age, gender, illness day on admission and year of admission were added into the model due to potential confounding. The Hosmer-Lemeshow goodness-of-fit test was conducted to ensure that the model fitted the data appropriately. In order to achieve the best discriminatory performance, 0.9 was being used as the minimum sensitivity for the cutoff. All tests were conducted at the 5% level of significance.

These analyses were carried out using R software version 3.0.2.[35]

Results
From 2005 to 2008, 4,383 adults hospitalized for dengue were dengue PCR-positive (n = 1494) or met the WHO criteria for probable dengue with a positive dengue serology (n = 2889). Of these, 188 patients (4.3%) experienced clinically significant bleeding after hospitalization. The breakdown was as follows: menorrhagia (44.7% of patients), hemoptysis (17%), hematemesis (11.2%), macroscopic hematuria (9%), fresh rectal bleeding (9%), melena (8.5%), and decrease in hemoglobin requiring transfusion (5.6%). None of the patients had intracranial bleeding. The proportion of dengue patients who had CSB during each year of the study period ranged from 3.4% in 2005 to 7.4% in 2007. A comparison of demographic features, co-morbidities, symptoms on admission and clinical outcomes among patients with and without CSB are shown in Table 1. Notably, in the cohort, 941 (21.5%) patients had dengue hemorrhagic fever, 158 (3.6%) had dengue shock syndrome, 15 (0.3%) were admitted to intensive care, and 1 died from dengue shock syndrome.

There were no statistically significant differences between the groups in terms of co-morbidities. The most commonly reported symptoms on admission were nausea and vomiting, myalgia, anorexia and fever in both groups. Univariate analysis (p < 0.05) showed that the following demographic features, clinical symptoms and laboratory results were significantly different on admission among patients who developed CSB compared with those who did not: female gender (p < 0.001), temperature > 38°C (p < 0.001); nausea/vomiting (p = 0.009); abdominal pain or tenderness (p = 0.005), systolic blood pressure less than 90 mmHg (p < 0.01), lower systolic blood pressure (p < 0.001), higher pulse rate (p < 0.001), decreased absolute lymphocyte count (ALC) (p < 0.001), reduced hematocrit percentage (p < 0.001), reduced platelet count (p = 0.04), and increased prothrombin time (PT; p = 0.003) (Table 1).

Multivariate analysis showed that the following factors were independently associated with CSB in adults with dengue: female gender, temperature > 38°C, increased ANC, decreased ALC and platelet count (Table 2). According to this analysis, women were 2.85 times as likely as men to develop CSB (95% CI: 1.9–4.33).

For each 0.5-unit increase in baseline ANC, the odds of CSB increased by 1.14 fold (aOR 1.14; 95% CI: 1.07–1.21), and for each 10-unit decrease in baseline platelet count, the odds of CSB increased by 1.07 fold (aOR 1.07; 95% CI: 1.02–1.13).
### Table 1. Demographic and clinical characteristics and outcomes among adult dengue patients with and without CSB.

| Variables                                      | CSB (n = 188) | No CSB (n = 4,195) | P-value        |
|-------------------------------------------------|---------------|--------------------|----------------|
| Demographics                                    |               |                    |                |
| Age (years)                                     | 36 (20–60)    | 34 (18–60)         | 0.28†          |
| Gender: Female                                  | 108 (57.4)    | 1,351 (32.2)       | <0.001†        |
| Ethnicity                                       |               |                    |                |
| Chinese                                         | 121 (64.3)    | 2,906 (69.3)       | 0.19           |
| Eurasian                                        | 0(0)          | 2(0.1)             | NA             |
| Indian                                          | 18 (9.6)      | 478 (11.4)         | NA             |
| Malay                                           | 16 (8.5)      | 294 (7)            | NA             |
| Others                                          | 33 (17.6)     | 33 (12.2)          | NA             |
| Year of admission                               |               |                    |                |
| 2005                                            | 94 (3.4)      | 2,694 (96.6)       | <0.001†        |
| 2006                                            | 22 (6.7)      | 307 (93.3)         | NA             |
| 2007                                            | 52 (7.4)      | 649 (92.6)         | NA             |
| 2008                                            | 20 (3.5)      | 545 (96.5)         | NA             |
| Co-morbidities                                  |               |                    |                |
| Diabetes mellitus                               | 10 (5.3)      | 146 (3.4)          | 0.22           |
| Hypertension                                    | 18 (9.5)      | 354 (8.4)          | 0.6            |
| Liver disease                                   | 2 (1.06)      | 30 (0.7)           | 0.65           |
| Renal disease                                   | 2 (1.06)      | 25 (0.6)           | 0.32           |
| Charlson’s co-morbidity score >3                | 1 (0.5)       | 12 (0.29)          | 0.43           |
| Symptoms on admission                           |               |                    |                |
| Temperature > 38°C                              | 117 (62.2)    | 1,687 (40.2)       | <0.001†        |
| Illness duration on first visit (days)           | 5 (3–7)       | 5 (3–7)            | 0.001†         |
| Myalgia                                         | 131 (69.7)    | 2,853 (68)         | 0.63           |
| Arthralgia                                      | 17 (9)        | 451 (10.8)         | 0.45           |
| Headache                                        | 90 (47.8)     | 2,003 (47.7)       | 0.97           |
| Back pain                                       | 18 (9.5)      | 360 (8.6)          | 0.6            |
| Chest pain                                      | 5 (2.6)       | 83 (2)             | 0.42           |
| Eye pain                                        | 2 (1.06)      | 97 (2.3)           | 0.44           |
| Anorexia                                        | 113 (60.1)    | 2,489 (59.3)       | 0.83           |
| Rash                                            | 63 (33.5)     | 1,688 (40.2)       | 0.06†          |
| Nausea/vomiting                                 | 149 (79.3)    | 2,985 (70.5)       | 0.009†         |
| Abdominal pain or tenderness                    | 65 (34.5)     | 1,068 (25.4)       | 0.005†         |
| Clinical fluid accumulation                     | 2 (1)         | 27 (0.3)           | 0.36           |
| Narrow pulse pressure                           | 3 (1.5)       | 21 (0.5)           | 0.08†          |
| Systolic blood pressure < 90 mm Hg              | 19 (10.1)     | 217 (5.1)          | <0.001†        |
| Systolic blood pressure (mm Hg)                 | 103 (82–129)  | 105 (89–130)       | <0.001†        |
| Pulse rate (beats per minute)                   | 94 (34–115)   | 89 (67–122)        | <0.001†        |
| White cell count (x10^3/mL)                     | 2.6 (1.3–6.2) | 2.7 (1.3–6.5)      | 0.21           |
| Absolute neutrophil count (ANC; x10^9/mL)       | 1.48 (0.49–4.34) | 1.4 (0.54–3.62) | 0.08†          |
| Absolute lymphocyte count (ALC; x10^9/mL)       | 0.5 (0.23–1.42) | 0.66 (0.26–2)   | <0.001†        |
| Hematocrit (%)                                  | 42.6 (34.4–51.0) | 44.5 (36.8–51.2) | <0.001†        |
| Creatinine (umol/L)                             | 76 (49–127)   | 78 (51–112)        | 0.06†          |
| Aspartate transaminase (U/L)                    | 113 (37–785)  | 113 (35–502)       | 0.18†          |
| Alanine aminotransferase (U/L)                  | 66 (20–591)   | 69 (20–350)        | 0.53           |
| Platelets (x10^9/mL)                            | 57 (18–131)   | 63 (18–126)        | 0.04†          |
| Prothrombin time (seconds)                      | 13.4 (12.1–16.9) | 13.1 (11.9–15.1) | 0.003          |
The stepwise model was deemed superior than the model using manual backward elimination with a higher sensitivity, specificity and model fit. The area under the curve (AUC) of the stepwise model was 0.758, and the Hosmer-Lemeshow goodness-of-fit showed the model fitted the data observed (p = 0.91).

Based on the final model, we created a probability equation with the patients’ relevant clinical data on admission:

\[
\text{Log odds (CSB)} = -0.04 - (1.05 \times \text{male gender}) + (0.59 \times \text{temperature} > 38^\circ \text{C}) + (0.3 \times \text{presence of nausea or vomiting}) + (0.27 \times \text{ANC}) + (0.9 \times \text{ALC}) - (0.04 \times \text{hematocrit percentage}) - (0.007 \times \text{platelet count})
\]

Patients with log odds greater than -3.919 were classified as having a high risk of developing CSB. Using this cutoff of -3.919 from the training data set, the sensitivity for the validation data set was 0.87 and the specificity was 0.38. The positive predictive value (PPV) was 0.06 but the negative predictive value (NPV) was 0.98.

Menorrhagia typically occurs in women of reproductive age, so it was suspected that this could explain the association of female gender with CSB. To test this hypothesis, patients with menorrhagia were excluded from a separate analysis. No female patient had a history abnormal menstrual bleeding. As expected, age and gender were excluded in the model without

### Table 1. (Continued)

| Variables | CSB (n = 188) | No CSB (n = 4,195) | P-value |
|-----------|---------------|-------------------|---------|
| Partial thromboplastin time (seconds) | 33.7 (43–66.9) | 41.2 (31.6–56.3) | 0.06 |

#### Clinical Outcomes

| Variable | CSB (n = 188) | No CSB (n = 4,195) | P-value |
|----------|---------------|-------------------|---------|
| Dengue hemorrhagic fever | 112 (59.5) | 829 (19.7) | <0.001 |
| Dengue shock syndrome | 33 (17.5) | 125 (3.0) | <0.001 |
| Platelet transfusion | 58 (9.6) | 130 (3.4) | <0.001 |
| Blood transfusion | 18 (9) | 1 (0.02) | <0.001 |
| Hospital length of stay (days) | 5 (3–10) | 4 (2–7) | <0.001 |
| Intensive care unit admission | 8 (4.2) | 7 (0.17) | <0.001 |
| Death | 3 (1.6) | 1 (0.02) | <0.001 |

Categorical variables are shown as the number and percentage of patients. For continuous variables, the median, 5th and 95th percentile is shown.

| Variable | CSB (n = 188) | No CSB (n = 4,195) | P-value |
|----------|---------------|-------------------|---------|
| Partial thromboplastin time (seconds) | 33.7 (43–66.9) | 41.2 (31.6–56.3) | 0.06 |

#### Table 2. Multivariate analysis of clinical factors on admission that were predictive of CSB according to the final model (N = 4383).

| Variables | Adjusted OR\(\) | (95% CI) |
|----------|------------------|---------|
| Female* | 2.85 | (1.9–4.33) |
| Temperature > 38°C* | 1.81 | (1.27–2.61) |
| Nausea/vomiting | 1.39 | (0.94–2.12) |
| ANC per 1 unit (x10^9/mL)* | 1.3 | (1.15–1.46) |
| ALC per 1 unit (x10^9/mL)* | 0.4 | (0.25–0.64) |
| Hematocrit per 1 unit (%) | 0.96 | (0.92–1.002) |
| Platelet per 1 unit (x10^9/mL)* | 0.993 | (0.988–0.998) |

*Adjusted for age, illness day at presentation and admission year

**Significant at 5% level

*Adjusted for age, illness day at presentation and admission year

**Significant at 5% level

Table 2. Multivariate analysis of clinical factors on admission that were predictive of CSB according to the final model (N = 4383).

Categorical variables are shown as the number and percentage of patients. For continuous variables, the median, 5th and 95th percentile is shown.

Percentages calculated over each year of admission

Included in the multivariate analysis

**Significant at 5% level
menorrhagia (Table 3), but the OR for temperature > 38°C, baseline ANC, ALC and platelet count remained significant through the model selection process, indicating that these variables were important risk factors for CSB in adult dengue patients, with or without menorrhagia. The model used for this secondary analysis showed an approximately similar discriminatory performance to the model that included menorrhagia (AUC, 0.737; sensitivity, 0.92; specificity, 0.35), which supported the findings that temperature > 38°C, baseline ANC, ALC and platelet count were associated with CSB. Aspartate aminotransferase (AST) emerged as a significant predictor after this secondary analysis, even though it was not associated with CSB in the final multivariate analysis (Table 2); however, the adjusted OR for AST was low (1.001; 95% CI: 1.000–1.002).

Females are known to have lower hematocrit values than males. We performed another set of sensitivity analysis stratified by gender. As shown in Table 4, we found that factors associated with clinically significant bleeding were slightly different between male and females. Variables included in the model with males only were temperature > 38°C, systolic blood pressure, hematocrit, ANC, ALC, platelet count, abdominal pain, nausea/vomiting. For females, variables included were temperature > 38°C, white cell count, ALC, platelet count and abdominal pain.

### Discussion

The annual proportion of adult dengue patients admitted to our hospital during the study period who developed CSB ranged from 3.4% to 7.4%. Knowledge of risk factors of CSB in

**Table 3. Secondary multivariate analysis (excluding menorrhagia) of clinical variables predictive of CSB in (n = 4299) adult dengue patients.**

| Predictors                        | aOR†     | (95% CI)    |
|-----------------------------------|----------|-------------|
| Temperature > 38°C*               | 1.95     | (1.2–3.2)   |
| ANC per 1 unit (x10⁹/mL)*         | 1.18     | (1.04–1.32) |
| ALC per 1 unit (x10⁹/mL)*         | 0.3      | (0.15–0.57) |
| Platelet count per 1 unit (x10⁹/mL) | 0.995  | (0.988–1.001) |
| AST per 1 unit (U/L)*             | 1.001    | (1.000–1.002) |

†Adjusted for age, gender, illness day at presentation and admission year
*Significant at 5% level

doi:10.1371/journal.pone.0148579.t003

**Table 4. Multivariate analysis of clinical variables predictive of CSB in adult dengue patients (stratified by gender).**

| Predictors                        | Male       | Female      |
|-----------------------------------|------------|-------------|
|                                  | aOR†  | (95% CI)   | aOR†  | (95% CI)   |
| Temperature > 38°C                | 1.68    | (1.2–2.4)* | 2.2    | (1.3–3.6)* |
| ALC per 1 unit (x10⁹/mL)          | 0.45    | (0.27–0.70)* | 0.36  | (0.18–0.72)* |
| Platelet count per 1 unit (x10⁹/mL) | 0.992 | (0.987–0.997)* | 0.993 | (0.985–0.999)* |
| Abdominal pain                    | 1.35    | (0.93–1.94) | 1.66    | (1.04–2.64)* |
| Nausea/vomiting                   | 1.6     | (1.04–2.5)* | -      | -          |
| Systolic blood pressure           | 0.985   | (0.972–0.999)* | -    | -          |
| ANC per 1 unit (x10⁹/mL)          | 1.23    | (1.06–1.4)* | -      | -          |
| Hematocrit per 1 unit (%)         | 0.916   | (0.883–0.949)* | -    | -          |
| White cell count (x10⁹/mL)        | -      | -          | 1.2    | (0.99–1.43) |

†Adjusted for age, illness day at presentation and admission year;
*Significant at 5% level

doi:10.1371/journal.pone.0148579.t004
adult dengue patients can assist with preparedness, improve patient management, and facilitate the appropriate use of limited resources.

This large retrospective study in adult patients hospitalized with dengue over a 4-year period showed that female gender, temperature >38°C, nausea/vomiting, increased ANC, and lowered ALC, hematocrit percentage and platelet counts were associated with CSB by multivariate analysis. Although nausea/vomiting and hematocrit percentage were not statistically significant with odds ratios crossing 1, they were still clinically important. Of the 188 adult dengue patients who had CSB, 44.5% had menorrhagia, which may explain the increased effects of female gender on multivariate analysis. Once patients with menorrhagia were excluded from the analysis, temperature >38°C, increased ANC and reduced ALC and platelet count remained as significant variables of CSB. AST appeared statistically significant in the secondary multivariate analysis which excluded menorrhagia, but the OR was very small. The fact that it was not revealed by the final multivariate analysis suggested a weak association in our patient population, particularly as the OR was small and the patient numbers were reduced. Another possible explanation is that AST was a risk factor of CSB in adult dengue patients without menorrhagia.

We also found that clinically significant bleeding in males and females was associated with different risk factors. There were, however, some variables that remained significant in both males and females, namely abdominal pain, platelet count, ALC and temperature >38°C. The latter three variables were significant in all four multivariable models.

Our findings are in agreement with those from several other studies. In a study of early predictors of clinically significant bleeding amongst 277 patients with dengue aged >15 years, multivariate analysis showed female gender (OR, 14.52; 95% CI: 0.16–0.56, p<0.001), absolute lymphocyte count >550/μl (OR 5.78; 95% CI: 1.17–4.99, p = 0.02) and severe thrombocytopenia (OR 4.72; 95% CI: 0.13–0.9, p = 0.03) to be independently related to clinically significant bleeding.[26] A case-control study of 59 dengue patients aged >17 years with or without bleeding showed that thrombocytopenia (OR 200; 95%CI: 22–1000; p = 0.0003), monocytosis (OR 13.5; 95% CI: 3.0–48.6; P < 0.0001) and elevated D-dimer (OR 14.9; 95% CI: 2.4–90; p = 0.0032) were the parameters most strongly associated with bleeding complications; ROC analysis showed that platelets < 67,000/mm³ (P < 0.0001, 94% sensitivity and 93% specificity) and monocytes > 715/mm³ (P < 0.0001, 84% sensitivity and 82% specificity) predicted dengue patients with bleeding.[29] In a large prospective cohort study of 643 patients aged 5 years or older who had acute febrile syndrome including dengue, the factors predictive of spontaneous non-cutaneous bleeding were age between 12 and 45 years (RR 2.22, 95% CI: 1.25–3.94), rash (RR 1.66; 95% CI: 1.25–2.2), vomiting (RR 1.46; 95% CI: 1.16–1.83), temperature >38°C (RR 2.63; 95% CI: 1.6–4.33), leukocyte count <4,500/μL (RR 1.87; 95% CI: 1.19–2.96), and platelet count <90,000/μL (RR 1.8; 95% CI: 1.1–2.94).[27] In a study of 132 children with or without spontaneous skin or mucosal bleeds, predictive factors for spontaneous bleeding derived from logistic regression analysis were platelet counts <50x10⁹/L, ALT more than 3 times the normal value, a biphasic pattern of fever, and abdominal pain.[30]

Factors other than those identified in our study, namely abdominal pain, hepatomegaly, pleural effusion and elevated liver enzymes [7,36], were associated with bleeding in other studies [7,28,36–38], but were not conclusively significant in ours. However, there were inconsistencies in the literature as to whether elevated liver transaminases were associated with dengue severity and with bleeding. A previous study in dengue patients at our center between 2006 and 2008 showed that, although aminotransferase levels did increase in conjunction with dengue severity, AST or ALT values did not discriminate between DF and DHF or non-severe and severe dengue.[39] AST and ALT levels were elevated in patients with DHF compared with those with DF in another South American study of patients aged >5 years, but they were not
independent predictors of severity.\textsuperscript{[40]} A prospective cohort study of 203 DF patients in South America showed that AST levels were higher in patients with DHF than those without, but that AST was not an independent predictor of disease severity in patients with DF.\textsuperscript{[40]} However, a meta-analysis has shown a strong association between elevated AST and ALT and dengue shock syndrome (DSS).\textsuperscript{[18]} Elevated AST/ALT levels were associated with clinically significant bleeding after univariate analysis in the Thai study mentioned above, but not after multivariate analysis.\textsuperscript{[26]} A prospective study on Vietnamese adults identified vomiting $\geq$3 times a day, lymphopenia, thrombocytopenia and elevated liver enzymes to be associated with plasma leakage, while elevated alanine aminotransferase with internal bleeding.\textsuperscript{[16]} A retrospective study of Singaporean adults showed that clinical bleeding, lymphopenia, elevated serum urea and low serum protein to be associated with dengue hemorrhagic fever.\textsuperscript{[13]}

Although our model managed to predict 86% of actual cases correctly, our cutoff also misclassified many non-CSB patients. The PPV reduces as the prevalence falls. The prevalence of CSB in our cohort was approximately 4%, which made achieving a high PPV difficult since the chance of developing CSB was low to begin with.\textsuperscript{[41]} The high NPV of 0.98 however may be useful for ruling out patients without CSB on admission. For example, a female patient admitted without nausea, fever and average ANC, ALC, hematocrit and platelet based on our cohort in Table 1 has a 9% chance of developing CSB.

Our retrospective study has some limitations. Firstly, it involved patients admitted at a single center. However, it included a range of ethnic groups that are fairly representative of the population of Southeast Asia. Secondly, we used laboratory values taken only on the day of admission, and dengue is a dynamic disease that can change from hour to hour. Dengue patients also tended to be admitted to our center at a later stage of disease [median day 5 (range, days 3–7) of illness in both groups] because it is a tertiary hospital, hence our findings may not be applicable in the earlier phase of dengue. However, given that most abnormal laboratory values observed over the course of dengue illness are seen during days 3–6 or even days 7–10 after the onset of illness [7,36,38,42], it is likely that, even though we only obtained measurement of these variables on the day of admission, the day of illness on which they were assessed would generally have been close to, the peak or nadir of abnormality. Thirdly, external validity may be limited as our adult cohort cannot be generalized to children. Further validation from other adult populations is needed as we could only split our data into one validation set. Lastly, the definition of menorrhagia in this paper was patient reported and classified by the doctor if patient had excessive amount of clots and number of pads than usual. It is difficult to measure the volume of menstrual bleeding clinically. There may be possible response bias but we felt that this was pragmatic for our circumstance. In addition, performing sensitivity analysis without menorrhagia reduced the number of cases substantially.

The strengths of our study are that it involved a large patient population that was admitted to our center over a relatively long period of time, during which the number of annual cases varied widely following multiple outbreaks, and the predominant serotype changed from dengue DENV1 to DENV2 in 2007.\textsuperscript{[43]}

In summary, we have identified several relevant clinical and laboratory markers that are associated with CSB in adult patients admitted to hospital for dengue which are particularly useful for ruling out patients with CSB. Healthcare personnel can view patients as safe from CSB when one or more of the following risk factors are absent: female gender, temperature $>$38°C, nausea/vomiting, increased neutrophil count, and decreased lymphocyte count, hematocrit and platelet counts. These findings, complemented with clinical judgement in reviewing new daily clinical and laboratory data given the dynamic nature of dengue disease progression, may provide an indication of patients that are safe not to admit to the hospital.
Supporting Information

S1 Checklist. STROBE checklist for cohort studies.

(DOC)

Acknowledgments

We are grateful to all our research assistants at the STOP Dengue Translational Clinical Research and patients who have participated in our study. We are thankful to Ms Adriana Tan for her support in data management and processing. Editorial assistance with preparation of the manuscript was provided by Dr Samantha Santangelo, PhD.

Author Contributions

Conceived and designed the experiments: YSL DCL. Performed the experiments: TLT YSL DCL. Analyzed the data: JGW. Contributed reagents/materials/analysis tools: TLT YSL DCL. Wrote the paper: JGW TLT YSL JXP DCL.

References

1. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. New ed. Geneva: World Health Organization; 2009.
2. Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Kloubučar A, Pem-Novosel I, et al. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011; 16. Available: http://www.ncbi.nlm.nih.gov/pubmed/21392489.
3. Hanna JN, Ritchie SA. Outbreaks of dengue in north Queensland, 1990–2008. Commun Dis Intell. 33.
4. Huhtamo E, Korhonen EM, Vapalahti O. Imported dengue virus serotype 1 from Madeira to Finland 2012. Eurosurveillance. 18. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20405.
5. Larrieu S, Dehecq JS, Baileydier E, Jaffar MC, Michault A, Vilain P, et al. Re-emergence of dengue in Réunion, France, January to April 2012. 17 May 2012. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20333.
6. Sousa CA, Clairouin M, Seixas G, Viveiros B, Novo MT, Silva AC, et al. Ongoing outbreak of dengue type 1 in the Autonomous Region of Madeira, Portugal: preliminary report. 2012. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20173.
7. Wichmann O, Gascon J, Schunk M, Puente S, Siikamaki H, Gjerup I, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis. 2007; 195: 1089–1096. doi:10.1086/512680 PMID: 17357044
8. WHO | Dengue and severe dengue. WHO. Available: http://www.who.int/mediacentre/factsheets/fs117/en/.
9. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013; 496: 504–507. doi: 10.1038/nature12060 PMID: 23563266
10. Wichmann O, Hongserimong S, Bowonwatanuwong C, Chotvaniich K, Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health. 2004; 9: 1022–1029. doi: 10.1111/j.1365-3156.2004.01295.x PMID: 15361117
11. Rowe EK, Leo Y-S, Wong JGX, Thein T-L, Gan VC, Lee DK, et al. Challenges in Dengue Fever in the Elderly: Atypical Presentation and Risk of Severe Dengue and Hospital-Acquired Infection. PLoS Negl Trop Dis. 2014; 8: e2777. doi: 10.1371/journal.pntd.0002777 PMID: 24699282
12. Dinh The T, Le Thi Thu T, Nguyen Minh D, Tran Van N, Tran Tinh H, Nguyen Van Vinh C, et al. Clinical Features of Dengue in a Large Vietnamese Cohort: Intrinsically Lower Platelet Counts and Greater Risk for Bleeding in Adults than Children. PLoS Negl Trop Dis. 2012; 6: doi: 10.1371/journal.pntd.0001679
13. Lee VJ, Ly DCB, Sun Y, Fernandez G, Ong A, Leo YS. Predictive value of simple clinical and laboratory variables for dengue hemorrhagic fever in adults. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2008; 42: 34–39. doi: 10.1016/j.jcv.2007.12.017
14. National Environment Agency. Factsheet on managing Singapore’s dengue outbreak. 2014. Available: http://www.nea.gov.sg/docs/default-source/corporate/COS-2015/cos-2015-media-factsheet—managing-dengue-outbreak_%282%29.pdf?sfvrsn=0.

15. Yacoub S, Wills B. Predicting outcome from dengue. BMC Med. 2014; 12: 147. doi: 10.1186/s12916-014-0147-9 PMID: 25259615

16. Binh PT, Matheus S, Huong VTQ, Deparis X, Marechal V. Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2009; 45: 276–280. doi: 10.1016/j.jcv.2009.04.004

17. Carrasco LR, Leo YS, Cook AR, Lee VJ, Thein TL, Go CJ, et al. Predictive Tools for Severe Dengue Conforming to World Health Organization 2009 Criteria. PLoS Negl Trop Dis. 2014; 8: e2972. doi: 10.1371/journal.pntd.0002972 PMID: 25010515

18. Huy NT, Van Giang T, Thuy DHD, Kikuchi M, Hien TT, Zamora J, et al. Factors Associated with Dengue Shock Syndrome: A Systematic Review and Meta-Analysis. PLoS Negl Trop Dis. 2013; 7: e2412. doi: 10.1371/journal.pntd.0002412 PMID: 24086778

19. Gupta V, Yadav TP, Pandey RM, Singh A, Gupta M, Kanaujiya P, et al. Risk Factors of Dengue Shock Syndrome in Children. J Trop Pediatr. 2011; 57: 451–456. doi: 10.1093/tropej/fmr020 PMID: 21367851

20. Zhang H, Zhou YP, Peng HJ, Zhang XH, Zhou FY, Liu ZH, et al. Predictive Symptoms and Signs of Severe Dengue Disease for Patients with Dengue Fever: A Meta-Analysis. BioMed Res Int. 2014; 2014: e359308. doi: 10.1155/2014/359308

21. Almas A, Parkash O, Akhter J. Clinical factors associated with mortality in dengue infection at a tertiary care center. Southeast Asian J Trop Med Public Health. 2010; 41: 333–340. PMID: 20578516

22. Branco MR, Luna EJ, Braga LL Jr, de Oliveira RV, Rios LT, Silva MS, et al. Risk factors associated with death in Brazilian children with severe dengue: a case-control study. Clinics. 2014; 59: 451–456. doi: 10.6061/clinics/2014(01)008

23. Thein T-L, Leo Y-S, Fisher DA, Low JG, Oh HML, Gan VC, et al. Risk Factors for Fatality among Confirmed Adult Dengue Inpatients in Singapore: A Matched Case-Control Study. PLoS ONE. 2013; 8: e81060. doi: 10.1371/journal.pone.0081060 PMID: 24278377

24. Lee I-K, Liu J-W, Yang KD. Fatal Dengue Hemorrhagic Fever in Adults: Emphasizing the Evolutionary Pre-fatal Clinical and Laboratory Manifestations. PLoS Negl Trop Dis. 2012; 6: e1532. doi: 10.1371/journal.pntd.0001532 PMID: 22363829

25. Channanachanunt S, Kanagaraj D, Thanachartwet V, Desakorn V, Rojnuckarin P. Early predictors of clinically significant bleeding in adults with dengue infection. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2012; 43: 890–899. PMID: 23077811

26. Diaz-Quijano FA, Villar-Centeno LA, Martinez-Vega RA. Predictors of spontaneous bleeding in patients with acute febrile syndrome from a dengue endemic area. J Clin Virol. 2010; 49: 11–15. doi: 10.1016/j.jcv.2010.06.011 PMID: 20663710

27. Fariz-Safhan MN, Tee HP, Abu Dzarr GA, Sapari S, Lee YY. Bleeding outcome during a dengue outbreak in 2005 in the East-coast region of Peninsular Malaysia: a prospective study. Trop Biomed. 2014; 31: 270–280. PMID: 25134959

28. Shivbalan DS, Anandnathan K, Balasubramanian S, Datta M, Amalraj E. Predictors of spontaneous bleeding in Dengue. Indian J Pediatr. 2004; 71: 33–36. doi: 10.1007/BF02725653 PMID: 14979383

29. Cavalcanti LP de G, Coelho ICB, Villar DCLF, Holanda SGS, da Escóssia KNF, Souza-Santos R. Clinical and epidemiological characterization of dengue hemorrhagic fever cases in northeastern, Brazil. Rev Soc Bras Med Trop. 2010; 43: 355–358. doi: 10.1590/S0037-86822010000400003 PMID: 20802929

30. Lee LK, Earnest A, Carrasco LR, Thein TL, Gan VC, Lee VJ, et al. Safety and cost savings of reducing adult dengue hospitalization in a tertiary care hospital in Singapore. Trans R Soc-Trop Med Hyg. 2013; 107: 37–42. doi: 10.1093/trstmh/trs009 PMID: 23296696

31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40: 373–383. doi: 10.1016/0021-9681(87)90171-8 PMID: 3558716
34. WHO | Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition. Geneva : World Health Organization. In: WHO [Internet]. [cited 24 Jun 2015]. Available: http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/.

35. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. 2013.

36. Kuo CH, Tai DI, Chang-Chien CS, Lan CK, Chiou SS, Liaw YF. Liver biochemical tests and dengue fever. Am J Trop Med Hyg. 1992; 47: 265–270. PMID: 1355950

37. Nguyen TL, Nguyen TH, Tieu NT. The impact of dengue haemorrhagic fever on liver function. Res Virol. 1997; 148: 273–277. doi: 10.1016/S0923-2516(97)88364-1 PMID: 9272578

38. Trung DT, Thao LTT, Hien TT, Hung NT, Vinh NN, Hien PTD, et al. Liver Involvement Associated with Dengue Infection in Adults in Vietnam. Am J Trop Med Hyg. 2010; 83: 774–780. doi: 10.4269/ajtmh.2010.10-0090 PMID: 20889864

39. Lee LK, Gan VC, Lee VJ, Tan AS, Leo YS, Lye DC. Clinical Relevance and Discriminatory Value of Elevated Liver Aminotransferase Levels for Dengue Severity. PLoS Negl Trop Dis. 2012; 6: e1676. doi: 10.1371/journal.pntd.0001676 PMID: 22679523

40. Villar-Centeno LA, Díaz-Quijano FA, Martínez-Vega RA. Biochemical Alterations as Markers of Dengue Hemorrhagic Fever. Am J Trop Med Hyg. 2008; 78: 370–374. PMID: 18337328

41. Loong T-W. Understanding sensitivity and specificity with the right side of the brain. BMJ. 2003; 327: 716–719. PMID: 14512479

42. Thein T-L, Lye DC, Leo Y-S, Wong JGX, Hao Y, Wilder-Smith A. Severe Neutropenia in Dengue Patients: Prevalence and Significance. Am J Trop Med Hyg. 2014; 90: 984–987. doi: 10.4269/ajtmh.14-0004 PMID: 24732460

43. Thein TL, Leo Y-S, Lee VJ, Sun Y, Lye DC. Validation of probability equation and decision tree in predicting subsequent dengue hemorrhagic Fever in adult dengue inpatients in singapore. Am J Trop Med Hyg. 2011; 85: 942–945. doi: 10.4269/ajtmh.2011.11-0149 PMID: 22049054